Clinical Guidelines

Repurposed Drugs Reshape Pricing Debate

Study models sustainable pricing for repurposed bevacizumab

  • March 19, 2026

  • 2 min

Share

A new formulation of bevacizumab, Lytenava, designed for ophthalmic use, is prompting reevaluation of pricing strategies for repurposed drugs. Originally an anticancer agent, bevacizumab is widely used off-label for retinal conditions due to its affordability compared to licensed alternatives that can cost over €700. Following Lytenava's approval, priced at £470, researchers introduced a cost-based pricing model projecting a more sustainable range of €73 to €177 per injection, emphasizing the need for transparent cost structures to foster equitable pricing discussions.

Original Source(s)

Repurposed Drugs Reshape Pricing Debate

  • March 19, 2026

Related Content

The European Myopia Network

A collaborative platform for myopia experts in Europe

Expanding the Therapeutic Landscape in Wet Age-related Macular Degeneration

The role of TKIs and sustained‑release delivery

Ophthalmology’s Role in the Opioid Crisis

Retrospective cohort study investigates how ophthalmologists can provide potentially life-saving care to substance use disorder patients